MX2023009445A - Compuestos de heterociclos tetraciclicos utiles como inhibidores de la integrasa del vih. - Google Patents

Compuestos de heterociclos tetraciclicos utiles como inhibidores de la integrasa del vih.

Info

Publication number
MX2023009445A
MX2023009445A MX2023009445A MX2023009445A MX2023009445A MX 2023009445 A MX2023009445 A MX 2023009445A MX 2023009445 A MX2023009445 A MX 2023009445A MX 2023009445 A MX2023009445 A MX 2023009445A MX 2023009445 A MX2023009445 A MX 2023009445A
Authority
MX
Mexico
Prior art keywords
tetracyclic heterocycle
heterocycle compounds
compounds useful
hiv integrase
integrase inhibitors
Prior art date
Application number
MX2023009445A
Other languages
English (en)
Spanish (es)
Inventor
Yonglian Zhang
Timothy John Hartingh
Tao Yu
John A Mccauley
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2023009445A publication Critical patent/MX2023009445A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MX2023009445A 2021-02-16 2022-02-14 Compuestos de heterociclos tetraciclicos utiles como inhibidores de la integrasa del vih. MX2023009445A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163149927P 2021-02-16 2021-02-16
PCT/US2022/016261 WO2022177840A1 (en) 2021-02-16 2022-02-14 Tetracyclic heterocycle compounds useful as hiv integrase inhibitors

Publications (1)

Publication Number Publication Date
MX2023009445A true MX2023009445A (es) 2023-08-25

Family

ID=80625127

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009445A MX2023009445A (es) 2021-02-16 2022-02-14 Compuestos de heterociclos tetraciclicos utiles como inhibidores de la integrasa del vih.

Country Status (12)

Country Link
US (1) US11958864B2 (cg-RX-API-DMAC7.html)
EP (1) EP4294813B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024507788A (cg-RX-API-DMAC7.html)
KR (1) KR20230147131A (cg-RX-API-DMAC7.html)
CN (1) CN117083282B (cg-RX-API-DMAC7.html)
AR (1) AR124868A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022223241B2 (cg-RX-API-DMAC7.html)
CA (1) CA3208396A1 (cg-RX-API-DMAC7.html)
ES (1) ES3048138T3 (cg-RX-API-DMAC7.html)
MX (1) MX2023009445A (cg-RX-API-DMAC7.html)
TW (1) TW202246286A (cg-RX-API-DMAC7.html)
WO (1) WO2022177840A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240151256A (ko) 2019-03-22 2024-10-17 길리애드 사이언시즈, 인코포레이티드 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
EP4110783A1 (en) 2020-02-24 2023-01-04 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
CN116390924B (zh) 2020-09-30 2025-11-07 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其用途
CR20260070A (es) 2021-01-19 2026-04-24 Gilead Sciences Inc COMPUESTOS DE PIRIDOTRIAZINA SUSTITUIDOS Y USOS DE ESTOS (Divisional 2023-0315)
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024226485A1 (en) * 2023-04-28 2024-10-31 Merck Sharp & Dohme Llc Delivery devices for anti-hiv compounds
WO2026101812A1 (en) * 2024-11-07 2026-05-15 Merck Sharp & Dohme Llc Hiv integrase inhibitors for treatment of hiv infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2660239B1 (en) * 2008-07-25 2016-11-23 VIIV Healthcare Company Chemical compounds as synthetic intermediates
WO2010011812A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
ES2395705T3 (es) * 2008-07-25 2013-02-14 Glaxosmithkline Llc Compuestos químicos
LT2620436T (lt) * 2010-09-24 2018-08-10 Shionogi & Co., Ltd. Pakeistojo policiklinio karbamoilpiridono darinio provaistas
WO2017113288A1 (en) * 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018140368A1 (en) * 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors

Also Published As

Publication number Publication date
WO2022177840A1 (en) 2022-08-25
CN117083282A (zh) 2023-11-17
ES3048138T3 (en) 2025-12-09
JP2024507788A (ja) 2024-02-21
KR20230147131A (ko) 2023-10-20
CA3208396A1 (en) 2022-08-25
CN117083282B (zh) 2026-05-29
AR124868A1 (es) 2023-05-10
US11958864B2 (en) 2024-04-16
EP4294813A1 (en) 2023-12-27
AU2022223241B2 (en) 2026-04-30
US20220259227A1 (en) 2022-08-18
AU2022223241A1 (en) 2023-08-24
TW202246286A (zh) 2022-12-01
EP4294813B1 (en) 2025-09-10

Similar Documents

Publication Publication Date Title
AR124868A1 (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
DOP2019000140A (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
DOP2023000168A (es) Compuestos antivirales que contienen nitrilo
UY37795A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
UY39032A (es) Compuestos heterocíclicos como agentes antivirales
ECSP16016726A (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
CO2021004679A2 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
MX2020011317A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih.
UY38559A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
UY38614A (es) Derivados de benzodiazepinas como inhibidores del rsv
MX2019006449A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih).
MX2012006297A (es) Uso topico hidroxitirosol y derivados para la prevencion de la infeccion por vih.
UY39642A (es) Compuestos heterocíclicos antivirales
CL2022002405A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
AR127470A1 (es) Inhibidores de lrrk2
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
CO2025003090A2 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
CL2025000672A1 (es) Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer.
MX2021009584A (es) Nuevos derivados de triterpeno como inhibidores del virus de la inmunodeficiencia humana (vih).
ECSP24007193A (es) Compuestos pirimidínicos para usar como inhibidores de map4k1
ECSP23075535A (es) Compuestos cíclicos y métodos de uso
UY40025A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno, y composiciones far
MX2023007716A (es) Procedimientos de tratamiento de enfermedades fibroticas.
MX2025014666A (es) Forma cristalina de sal sodica de derivados de piridona carbamoilica policiclica, su metodo de preparacion y aplicacion
UY39738A (es) Compuestos antivirales que contienen nitrilo